MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$8.203M
EPS
-$0.18
Unit: Million (M) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
6.019
6.743
9*
7
General and administrative
2.885
3.808
3*
3.04
Total operating expenses
8.904
10.551
12
10.04
Loss from operations
-8.904
-10.551
-12*
-10.04
Interest income
0.72
0.523
1*
0.687
Other expense
-0.001
-
0*
-
Net loss attributable to common stockholders
-8.185
-10.028
-11*
-9.353
Unrealized loss on investments
-0.018
-0.062
0*
0.039
Comprehensive loss
-8.203
-10.09
-11
-9.314
Basic EPS
-0.18
-0.29
-0.379
-0.31
Diluted EPS
-0.18
-0.29
-0.379
-0.31
Basic Average Shares
44,760,766
34,059,876
30,198,683
30,276,230
Diluted Average Shares
44,760,766
34,059,876
30,198,683
30,276,230
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$8.203M
(-26.49%↓ Y/Y)
Net loss
attributable to common...
-$8.185M
(-26.66%↓ Y/Y)
Unrealized loss on
investments
-$0.018M
(21.74%↑ Y/Y)
Interest income
$0.72M
(-4.51%↓ Y/Y)
Loss from operations
-$8.904M
(-23.39%↓ Y/Y)
Other expense
-$0.001M
Total operating
expenses
$8.904M
(23.39%↑ Y/Y)
Research and development
$6.019M
(88.09%↑ Y/Y)
General and
administrative
$2.885M
(-28.16%↓ Y/Y)
Buy us a coffee
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)